Argos Therapeutics (ARGS) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to Argos Therapeutics (ARGS) Misses Q1 EPS by 9c

Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights

May 14, 2015 4:05 PM EDT

-Interim data analyses from the phase 3 ADAPT trial at approximately 25% of events expected during ASCO Annual Meeting-

- Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET -

DURHAM, N.C., May 14, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform, today reported financial results for the first quarter ended March 31, 2015 and provided an update on the Company's clinical... More